ISO 10993 is a series of international standards for the biological evaluation of medical devices. It defines how to assess biocompatibility, the biological safety of materials and components that contact the body, using a risk-based process that matches the required tests to the nature and duration of patient contact.
What is ISO 10993?
ISO 10993, titled “Biological evaluation of medical devices,” is a multi-part standard family. The anchor part, ISO 10993-1, sets the framework: it requires a structured biological evaluation conducted within a risk management process rather than a fixed checklist of tests. The remaining sections describe specific endpoints and methods, including cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, implantation effects, hemocompatibility, and chemical characterization.
Biocompatibility falls within the design and verification phase of the device lifecycle, but it also touches on material selection, supplier control, sterilization, and labeling. The evaluation considers the finished, sterilized device in its final form, not just raw materials, because processing and packaging can change what the body is actually exposed to.
Why ISO 10993 Matters in Medical Device Development
A device that contacts tissue, blood, or mucosa can cause harm if its materials leach toxic chemicals, trigger sensitization, or degrade unpredictably. ISO 10993 is the recognized basis for demonstrating that those risks have been evaluated and controlled.
Regulators expect it. The FDA recognizes ISO 10993-1 and issues its own guidance on applying it, and the EU MDR 2017/745 requires biocompatibility evidence under its general safety and performance requirements. A weak or incomplete biological evaluation is one of the more common reasons for submission delays. Test programs are also expensive and slow, so a poorly planned evaluation adds cost and delays time-to-market. Strong biological evaluation files reduce audit exposure and rework late in development.
How the ISO 10993 Process Works
ISO 10993-1 frames biocompatibility as a risk-based exercise. The general flow is:
- Categorize the device. Classify it by the nature of body contact (surface, external communicating, or implant) and by contact duration (limited, prolonged, or long-term). This determines which biological endpoints apply.
- Gather material and process data. Identify all materials, additives, processing aids, and sterilization methods that could affect what reaches the patient.
- Run chemical characterization. Per ISO 10993-18, identify and quantify extractables and leachables from the finished device.
- Assess toxicological risk. Per ISO 10993-17, evaluate identified chemicals against tolerable exposure levels to decide whether they raise concern.
- Close gaps with testing. Where existing data and characterization are insufficient, conduct biological tests for the relevant endpoints (for example, ISO 10993-5 for cytotoxicity, ISO 10993-23 for irritation, ISO 10993-10 for sensitization).
- Document the conclusion. Record the rationale, data, and residual risk in a biological evaluation report (BER) tied to the ISO 14971 risk management file.
The standard interlocks with other frameworks. Risk decisions align with ISO 14971, sterilization residuals align with ISO 10993-7, and the whole effort lives within an ISO 13485 quality system.
Common Challenges and Best Practices
The most frequent mistake is treating ISO 10993 as a list of tests to order rather than a risk assessment. Teams that test first and reason later often spend money on endpoints that a sound chemical characterization could have addressed, or miss endpoints that actually apply.
Another common gap is evaluating the raw material rather than the final, sterilized, packaged device. Coatings, adhesives, mold-release agents, and sterilization byproducts can all change the biological profile.
Good practice starts the biological evaluation early, during material selection, so problem chemistries are designed out before tooling is committed. Modern programs rely on chemical characterization and toxicological risk assessment to limit animal testing, aligning with both regulatory expectations and ISO 10993-2 animal welfare principles. Keep the biological evaluation plan and report living documents, and revisit them whenever a material, supplier, or sterilization method changes.
How SJML Helps with ISO 10993
SJML supports biological safety as part of its regulatory and design services. Its teams plan the biological evaluation, build the material and process inventory, and fold biocompatibility into the ISO 14971 risk management file and the technical documentation needed for FDA and EU MDR/IVDR submissions. Materials-of-concern screening (RoHS, REACH/SVHC, and related controls) informs material selection, helping catch problem chemistries early. Specialist biological testing is run through qualified, accredited laboratories, with SJML managing strategy, gap analysis, and the biological evaluation report.
Talk to SJML’s QARA team →
Frequently Asked Questions
Not always as full testing. ISO 10993-1 requires a biological evaluation, but it may rely on existing data, chemical characterization, and toxicological risk assessment. Actual biological tests are needed only to close gaps that those sources cannot. The scope depends on the device’s contact type and duration, so a short-contact-surface device requires far less than a long-term implant.
ISO 10993 covers biological safety, the risk that device materials harm the body through contact. ISO 14971 is the broader risk management standard covering all device hazards. They connect directly: the biological evaluation under ISO 10993 produces inputs and conclusions that feed the ISO 14971 risk file, where biocompatibility risks are documented alongside mechanical, electrical, and use-related risks.
ISO 10993-5 specifies in vitro cytotoxicity test methods. Cytotoxicity is usually one of the first endpoints assessed because it is sensitive and applies to almost every contacting device. A failed cytotoxicity result is an early signal that a material or process introduces something harmful, prompting investigation before more costly endpoints are run.
Yes. EU MDR 2017/745 requires evidence of biocompatibility under its general safety and performance requirements, and ISO 10993 provides the harmonized basis for demonstrating it. The biological evaluation report becomes part of the technical documentation reviewed for CE marking. FDA submissions rely on the same standard through FDA’s recognition of ISO 10993-1.
Related Terms
- Biocompatibility Testing
- ISO 14971
- Design Verification
- Design Validation
- ISO 13485
